Re-examination board – Aitken Klee LLP

Re-Examination Board affirms validity of Teva’s Copaxone patent

07 Nov 2022

Teva’s 802 Patent claims a dosing regimen for treating multiple sclerosis with Copaxone (glatiramer acetate). The Federal Court held the 802 Patent...